MX2015005481A - Metodos para tratar enfermedades asociadas con s. aureus. - Google Patents
Metodos para tratar enfermedades asociadas con s. aureus.Info
- Publication number
- MX2015005481A MX2015005481A MX2015005481A MX2015005481A MX2015005481A MX 2015005481 A MX2015005481 A MX 2015005481A MX 2015005481 A MX2015005481 A MX 2015005481A MX 2015005481 A MX2015005481 A MX 2015005481A MX 2015005481 A MX2015005481 A MX 2015005481A
- Authority
- MX
- Mexico
- Prior art keywords
- aureus
- methods
- treating
- preventing
- reducing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 101710092462 Alpha-hemolysin Proteins 0.000 abstract 3
- 101710197219 Alpha-toxin Proteins 0.000 abstract 3
- 101710124951 Phospholipase C Proteins 0.000 abstract 3
- 239000002776 alpha toxin Substances 0.000 abstract 3
- 206010061598 Immunodeficiency Diseases 0.000 abstract 2
- 206010035664 Pneumonia Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000031729 Bacteremia Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona métodos para prevenir y/o tratar la bacteriemia y la septicemia asociadas con S. aureus, y métodos para prevenir y/o tratar la neumonía asociada con S. aureus en pacientes inmunodeprimidos utilizando anticuerpos contra la toxina alfa de S. aureus (anti-TA). También se proporcionan métodos para reducir la carga bacteriana de S. aureus en el torrente sanguíneo o el corazón de un sujeto que es un mamífero, que comprenden administrar al sujeto una cantidad efectiva de un anticuerpo contra la toxina alfa de S. aureus (anti-TA) aislado o un fragmento de unión al antígeno de este. También se proporcionan métodos para reducir la aglutinación bacteriana y/o formación de lesiones tromboembólicas en un sujeto que es un mamífero, que comprenden administrar al sujeto una cantidad efectiva de un anticuerpo contra la toxina alfa de S. aureus (anti-TA) aislado o un fragmento de unión al antígeno de este. También se proporcionan métodos para prevenir o reducir la gravedad de la neumonía asociada con S. aureus en un sujeto que es un mamífero inmunodeprimido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723128P | 2012-11-06 | 2012-11-06 | |
| PCT/US2013/068385 WO2014074470A1 (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005481A true MX2015005481A (es) | 2016-01-14 |
| MX367082B MX367082B (es) | 2019-08-05 |
Family
ID=50685101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005481A MX367082B (es) | 2012-11-06 | 2013-11-05 | Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9845348B2 (es) |
| EP (1) | EP2928490B1 (es) |
| JP (2) | JP6506172B2 (es) |
| KR (3) | KR20150092738A (es) |
| CN (2) | CN112316135A (es) |
| AU (2) | AU2013341421A1 (es) |
| BR (1) | BR112015010126B1 (es) |
| CA (1) | CA2890385C (es) |
| ES (1) | ES2912267T3 (es) |
| HK (1) | HK1215173A1 (es) |
| MX (1) | MX367082B (es) |
| RU (1) | RU2661406C2 (es) |
| SG (2) | SG10201703677VA (es) |
| WO (1) | WO2014074470A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57024B1 (sr) | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
| LT2776065T (lt) * | 2011-11-07 | 2020-10-12 | Medimmune Limited | Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules |
| ES2912267T3 (es) * | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| AU2013341361A1 (en) * | 2012-11-06 | 2015-06-04 | Medimmune, Llc | Antibodies to S. aureus surface determinants |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| US11155606B2 (en) | 2018-07-24 | 2021-10-26 | Medimmune, Llc | Antibody directed against S. aureus clumping factor a (ClfA) |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| TW202028232A (zh) | 2018-10-09 | 2020-08-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053235A1 (en) | 2006-06-12 | 2009-02-26 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| WO2009029831A1 (en) | 2007-08-31 | 2009-03-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| WO2011008939A2 (en) * | 2009-07-16 | 2011-01-20 | Medical College Of Georgia Research Institute, Inc. | Porous-wall hollow glass microspheres as carriers for biomolecules |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| AU2012214677B2 (en) * | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| CA2826566C (en) * | 2011-02-08 | 2022-09-13 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| ES2912267T3 (es) * | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| AU2013341361A1 (en) | 2012-11-06 | 2015-06-04 | Medimmune, Llc | Antibodies to S. aureus surface determinants |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
-
2013
- 2013-11-05 ES ES13853844T patent/ES2912267T3/es active Active
- 2013-11-05 JP JP2015540852A patent/JP6506172B2/ja active Active
- 2013-11-05 AU AU2013341421A patent/AU2013341421A1/en not_active Abandoned
- 2013-11-05 US US14/440,749 patent/US9845348B2/en active Active
- 2013-11-05 KR KR1020157011460A patent/KR20150092738A/ko not_active Application Discontinuation
- 2013-11-05 MX MX2015005481A patent/MX367082B/es active IP Right Grant
- 2013-11-05 SG SG10201703677VA patent/SG10201703677VA/en unknown
- 2013-11-05 WO PCT/US2013/068385 patent/WO2014074470A1/en active Application Filing
- 2013-11-05 RU RU2015121617A patent/RU2661406C2/ru active
- 2013-11-05 CN CN202011217117.7A patent/CN112316135A/zh active Pending
- 2013-11-05 SG SG11201503231YA patent/SG11201503231YA/en unknown
- 2013-11-05 CN CN201380057604.3A patent/CN104780934A/zh active Pending
- 2013-11-05 EP EP13853844.2A patent/EP2928490B1/en active Active
- 2013-11-05 BR BR112015010126-7A patent/BR112015010126B1/pt active IP Right Grant
- 2013-11-05 KR KR1020217020104A patent/KR20210083389A/ko not_active Application Discontinuation
- 2013-11-05 KR KR1020207024078A patent/KR102272744B1/ko active IP Right Grant
- 2013-11-05 CA CA2890385A patent/CA2890385C/en active Active
-
2016
- 2016-03-18 HK HK16103165.5A patent/HK1215173A1/zh unknown
-
2017
- 2017-12-18 US US15/845,701 patent/US10457724B2/en active Active
-
2018
- 2018-09-28 AU AU2018236849A patent/AU2018236849B2/en active Active
-
2019
- 2019-03-28 JP JP2019063358A patent/JP6926138B2/ja active Active
- 2019-10-11 US US16/599,595 patent/US10759849B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005481A (es) | Metodos para tratar enfermedades asociadas con s. aureus. | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| NZ709997A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| NZ630363A (en) | Anti-kit antibodies and uses thereof | |
| WO2013119716A8 (en) | Compositions and methods for using csf1r inhibitors | |
| MX2015006681A (es) | Formulaciones de vancomicina estabilizadas. | |
| MX2020009700A (es) | Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso. | |
| MX2018010776A (es) | Moleculas de union de antigeno multiespecificas y usos de las mismas. | |
| MX362720B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| BR112015010125A2 (pt) | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| MX2013012393A (es) | Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| MX347454B (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
| MX2015007147A (es) | Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab. | |
| SG10201804809RA (en) | Clostridium difficile antibodies | |
| TW201613575A (en) | Treatment of polybacterial infections | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| AU2018256482A1 (en) | Antibodies Against Clostridium Difficile | |
| GB201109238D0 (en) | Antibodies | |
| EP3492101A3 (en) | Agents for influenza neutralization | |
| MX360857B (es) | Régimen de dosificación para inhibidores de janus quinasa (jak). | |
| MX357708B (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |